A Study of Urine Volatile Organic Compounds for Disease Detection (TOBY ATLAS)
TOBY ATLAS: A Multi-Site, Non-Interventional Study of Urinary Volatile Organic Compounds
The goal of this observational study is to develop and evaluate urine tests for detecting disease in adults. It will initially focus on prostate, bladder, and kidney cancer. Researchers will compare urine samples and medical records from people with and without these diseases to see whether the tests can detect them accurately. Participants may provide a urine sample during a routine visit. Study results will not be returned to participants or used in their care.
Studieoversigt
Status
Status
Betingelser
Betingelser
Detaljeret beskrivelse
TOBY ATLAS is a multi-center master protocol that supports the development and validation of urine-based tests for screening, diagnosis, and monitoring of multiple diseases. The study uses prospectively collected, residual, banked, and purchased urine samples, where permitted.
Researchers will analyze urine for volatile organic compounds using gas chromatography-mass spectrometry and develop models using samples with known disease status. Each model will be locked before it is evaluated using a separate set of blinded samples.
Disease status and available standard-of-care test results will be obtained from medical records. Researchers may also review records over time to identify later diagnoses or outcomes. Sites and diseases may be added as the study progresses.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: TOBY ATLAS Study Team
- Telefonnummer: 309-592-8898
- E-mail: info@toby.health
Undersøgelse Kontakt Backup
- Navn: TOBY ATLAS Study Team
- E-mail: press@toby.health
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Adults with target diseases and comparison participants, including healthy volunteers and individuals with other diseases, benign conditions, or negative diagnostic work-ups. Participants are identified through routine care and other permitted specimen sources.
Beskrivelse
Inclusion Criteria:
- Age 50 years or older, or another age range set in the applicable disease specification (for example, 45 or older for colorectal cancer).
- Informed consent, or eligibility under an exemption or waiver for waste, residual, banked, or purchased specimens.
- Medical records available for the reference standard.
- Meets the case or control definition and other inclusion criteria in at least one disease specification, or belongs to the Healthy Control Set.
Exclusion Criteria:
- Any exclusion stated in the applicable disease specification.
- Symptomatic urinary tract infection at collection, unless enrolled as a confounder control.
- Current pregnancy, imprisonment, or inability to consent for oneself (consented route).
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: CASE_CONTROL
- Tidsperspektiver: PROSPECTIVE
Antal grupper/kohorter
Kohorter og interventioner
Gruppe / kohorteGruppe / kohorte |
|---|
|
Target disease cases
Participants with a target disease established by the applicable reference standard, including participants assessed after treatment where specified. |
|
Controls
Participants without the target disease for a given analysis, including healthy participants and participants with other diseases, benign conditions, or negative diagnostic work-ups. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Clinical performance of each locked assay
Tidsramme: At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.
|
Sensitivity and specificity at pre-specified thresholds, and area under the receiver operating characteristic curve, of each locked assay against the applicable reference standard in its intended-use population, using blinded validation specimens not used to develop that assay. Estimates will include 95% confidence intervals. |
At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.
|
|
Paired comparison with available standard-of-care tests
Tidsramme: At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.
|
Differences in sensitivity, specificity, and area under the receiver operating characteristic curve between each locked assay and each available standard-of-care test in the same participants, with 95% confidence intervals. |
At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Assay performance by subgroup and signal origin
Tidsramme: At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.
|
Sensitivity, specificity, and area under the receiver operating characteristic curve across thresholds and by disease characteristics, populations, and control types, including stage, grade, and age; accuracy of signal-origin classification. |
At specimen collection and reference-standard assessment, including medical-record review at approximately 12 months where available.
|
|
Protocol-conforming specimens with final reference-standard classification
Tidsramme: From specimen collection through reference-standard classification, including medical-record review at approximately 12 months where available.
|
Number of protocol-conforming urine specimens with final reference-standard classification, summarized by disease and control type. |
From specimen collection through reference-standard classification, including medical-record review at approximately 12 months where available.
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Candidate assays advanced to validation
Tidsramme: From study start through study completion, estimated up to 5 years
|
Number of candidate assays developed using the Development Pool that are locked and carried forward to a Validation Plan. |
From study start through study completion, estimated up to 5 years
|
|
Exploratory prognostic and simulated clinical and economic outcomes
Tidsramme: Up to 5 years after specimen collection, where follow-up is permitted and available
|
Where optional medical-record follow-up is available, compare progression, recurrence, treatment response, stage at diagnosis, procedures, health care use, and costs with blinded assay predictions. These are exploratory prognostic and simulated health-economic analyses; test results are not used in care. |
Up to 5 years after specimen collection, where follow-up is permitted and available
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- TOBY-ATLAS-001
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
There is currently no plan to make individual participant data available to other researchers.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .